Diethylpropion
Active ingredient: Diethylpropion Hydrochloride
In short: Diethylpropion hydrochloride is indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m 2or higher and who have not responded to appropriate weigh
What is Diethylpropion used for?
Diethylpropion hydrochloride is indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m
2or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of BMI based on various heights and weights. BMI is calculated by taking the patientβs weight, in kilograms (kg), divided by the patientβs height, in meters (m), squared. Metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters.
Weight (pounds) | Height (feet, inches)
5β0β | 5β3β | 5β6β | 5β9β | 6β0β | 6β3β
140 | 27 | 25 | 23 | 21 | 19 | 18
150 | 29 | 27 | 24 | 22 | 20 | 19
160 | 31 | 28 | 26 | 24 | 22 | 20
170 | 33 | 30 | 28 | 25 | 23 | 21
180 | 35 | 32 | 29 | 27 | 25 | 23
190 | 37 | 34 | 31 | 28 | 26 | 24
200 | 39 | 36 | 32 | 30 | 27 | 25
210 | 41 | 37 | 34 | 31 | 29 | 26
220 | 43 | 39 | 36 | 33 | 30 | 28
230 | 45 | 41 | 37 | 34 | 31 | 29
240 | 47 | 43 | 39 | 36 | 33 | 30
250 | 49 | 44 | 40 | 37 | 34 | 31
The usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described below. Diethylpropion hydrochloride is indicated for use as monotherapy only.
β Boxed warning (FDA's strongest warning)
Diethylpropion hydrochloride should not be used in combination with other anorectic agents, including prescribed drugs, over-the-counter preparations, and herbal products.
In a case-control epidemiological study, the use of anorectic agents, including diethylpropion, was associated with an increased risk of developing pulmonary hypertension, a rare, but often fatal disorder. The use of anorectic agents for longer than 3 months was associated with a 23-fold increase in the risk of developing pulmonary hypertension. Increased risk of pulmonary hypertension with repeated courses of therapy cannot be excluded.
The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, diethylpropion hydrochloride should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other anorectic drugs. Valvulopathy has been very rarely reported with diethylpropion hydrochloride monotherapy, but the causal relationship remains uncertain.The potential risk of possible serious adverse effects such as valvular heart disease and pulmonary hypertension should be assessed carefully against the potential benefit of weight loss. β¦
Diethylpropion dosage
Diethylpropion hydrochloride immediate-release:
One immediate-release 25 mg tablet three times daily, one hour before meals, and in midevening if desired to overcome night hunger.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Warnings & precautions
Do not take this medicine if: Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension.
Agitated states.
Patients with a history of drug abuse.
Use in combination with other anorectic agents is contraindicated.
During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result.
Caution is to be exercised in prescribing diethylpropion hydrochloride for patients with hypertension or with symptomatic cardiovascular disease, including arrhythmias. Diethylpropion hydrochloride should not be administered to patients with severe hypertension.
Reports suggest that diethylpropion hydrochloride may increase convulsions in some epileptics. Therefore, epileptics receiving diethylpropion hydrochloride should be carefully monitored. Titration of dose or discontinuance of diethylpropion hydrochloride may be necessary.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
The patient should be cautioned about concomitant use of alcohol or other CNS-active drugs and diethylpropion hydrochloride. The patient should be advised to observe caution when driving or engaging in any potentially hazardous activity.
None.
Because diethylpropion hydrochloride is a monoamine, hypertension may result when this agent is used with monoamine oxidase (MAO) inhibitors .
Efficacy of diethylpropion with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems; therefore, the concomitant use with other anorectic agents is contraindicated.
Antidiabetic drug requirements (i.e., insulin) may be altered. Concurrent use with general anesthetics may result in arrhythmias. β¦
Diethylpropion side effects
Cardiovascular:Precordial pain, arrhythmia (including ventricular), ECG changes, tachycardia, elevation of blood pressure, palpitation and rare reports of pulmonary hypertension. Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine, both independently and especially when used in combination, have been reported. Valvulopathy has been very rarely reported with diethylpropion hydrochloride monotherapy, but the causal relationship remains uncertain.
Central Nervous System:In a few epileptics an increase in convulsive episodes has been reported; rarely psychotic episodes at recommended doses; dyskinesia, blurred vision, overstimulation, nervousness, restlessness, dizziness, jitteriness, insomnia, anxiety, euphoria, depression, dysphoria, tremor, mydriasis, drowsiness, malaise, headache, and cerebrovascular accident
Gastrointestinal:Vomiting, diarrhea, abdominal discomfort, dryness of the mouth, unpleasant taste, nausea, constipation, other gastrointestinal disturbances
Allergic:Urticaria, rash, ecchymosis, erythema
Endocrine:Impotence, changes in libido, gynecomastia, menstrual upset
Hematopoietic System:Bone marrow depression, agranulocytosis, leukopenia
Miscellaneous:A variety of miscellaneous adverse reactions has been reported by physicians. These include complaints such as dysuria, dyspnea, hair loss, muscle pain, increased sweating, and polyuria.
About this medicine
Diethylpropion hydrochloride is available for oral administration in immediate-release tablets containing 25 mg diethylpropion hydrochloride. The inactive ingredients in each immediate-release tablet are: crospovidone, lactose anhydrous, magnesium stearate, starch pregelatinized and tartaric acid. Diethylpropion hydrochloride is a sympathomimetic agent. The chemical name for diethylpropion hydrochloride is 1-phenyl-2-diethylamino-1-propanone hydrochloride.
Its chemical structure is:
How it works: Diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Actions include some central nervous system stimulation and elevation of blood pressure. Tolerance has been demonstrated with all drugs of this class in which these phenomena have been looked for.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ad0c3dc9-ae13-4853-bc8c-a66e2a69cc10. Read the full official label on DailyMed.
Related medicines
Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Orlistat Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine